Business Context and Reporting Period
Company: BioSig Technologies, Inc. (Note: Input metadata referenced "Streamex Corp.", but the filing text identifies the registrant as BioSig Technologies, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: BioSig is a medical device company developing the PURE EP System for cardiac electrophysiology. The company operates through three segments: BioSig Technologies (parent), ViralClear Pharmaceuticals, and BioSig AI Sciences. The company is currently in an early commercialization stage with minimal revenue and significant accumulated deficits.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Total Revenue | $27 | $5 |
| Net Loss (Attributable to Common Shareholders) | $(7,455) | $(18,430) |
| Operating Expenses | $8,756 | $18,299 |
| Cash and Cash Equivalents (End of Period) | $2,104 | $1,252 |
| Net Cash Used in Operating Activities | $(2,795) | $(10,543) |
| Net Cash Provided by Financing Activities | $4,709 | $11,560 |
| Working Capital Deficit | $(590) | N/A |
| Total Assets | $3,107 | $1,798 |
| Total Liabilities | $2,991 | $4,685 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $27,000 for the six months ended June 30, 2024, compared to $5,000 in the prior year period, driven by service revenue.
- Expense Reduction: Total operating expenses decreased significantly by approximately 52% to $8.76 million from $18.3 million in the prior year. This was primarily due to a major workforce reduction in early 2024 (layoffs of 42 employees, including the COO and Chief Commercial Officer) and reduced consulting fees.
- Net Loss Improvement: Net loss attributable to common shareholders decreased to $7.46 million from $18.43 million year-over-year, largely due to the reduction in operating expenses and a one-time gain on the settlement and forgiveness of accounts payable ($1.39 million).
- Asset Impairment: The company recorded a $253,000 impairment charge on long-term assets during the six months ended June 30, 2024, due to reduced manufacturing activity.
- Capital Structure: The company completed a 1-for-10 reverse stock split effective February 2, 2024. Additionally, the conversion price of Series C Preferred Stock was reset, resulting in a non-cash deemed dividend of $133,000.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that the company's net losses, negative cash flows, and working capital deficit raise substantial doubt about its ability to continue as a going concern. The company requires additional financing to fund future operations.
- Delisting and Trading Status: BioSig was delisted from the Nasdaq Capital Market on June 12, 2024, due to non-compliance with minimum stockholders' equity and bid price requirements. The stock now trades on the OTCQB market under the symbol "BSGM". The company is appealing the delisting decision.
- Unusual Items:
- Gain on Debt Settlement: A $1.39 million gain was recognized from the settlement and forgiveness of accounts payable.
- Stock for Debt/Services: Significant equity issuances occurred to settle debt (conversion of a $500k related-party note) and pay for services (consultants and employees), totaling over 2 million shares issued in the period.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, specifically regarding stock-based compensation recording, period-end review processes, and segregation of duties.
- Strategic Shift: Management plans to hire a small team (4-6 persons) focused on business development and partnerships to commercialize the PURE EP system, aiming to reduce cash burn.
- Subsequent Event: On July 1, 2024, the company announced a non-binding letter of intent to acquire assets from Neuro-Kinesis Corporation (NKC), potentially receiving $2.5 million to $6 million in cash at closing.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $2.1 million cash balance against the current burn rate and the timeline for securing additional financing.
- Delisting Appeal Status: Monitor the outcome of the appeal to the Nasdaq Listing and Hearing Review Council and the impact of trading on the OTCQB market on liquidity and valuation.
- Acquisition Progress: Track the due diligence and shareholder approval process for the proposed acquisition of Neuro-Kinesis Corporation assets.
- Legal Proceedings: Review the status of pending litigation, including the lawsuit filed by Michael Gray Fleming seeking $288,000 and other threatened claims totaling over $2 million.
- Internal Control Remediation: Assess the company's plan to remediate material weaknesses in financial reporting to ensure future compliance and accurate disclosure.
- Revenue Concentration: Note that 100% of revenue in Q2 2024 came from a single customer, creating significant concentration risk.